Participant flow

Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation · Source last updated 2017-06-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Denileukin Diftitox (Ontak) administered Post Autologous Transplantation. Denileukin Diftitox (Ontak) : After receiving their stem cell transplant on Day 0, participants will receive study agent via a 30 minute infusion. Participants will also receive a 30 minute infusion of study agent on Day 21. Follow-up visits for clinical assessment, blood draws for routine clinical laboratory studies and for immuno-correlative studies will also take place on days 42, 90, 180 and 360.

   id

   FG000

   title

   Denileukin Diftitox (Ontak)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Adverse Event

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         2

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Cancer center clinic.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice